Otonomy, Zosano queue for IPOs; Startups eye a robotic chemist;

@FierceBiotech: Can GlaxoSmithKline go from 0 to 150 on an Ebola vaccine program? Story | Follow @FierceBiotech

@JohnCFierce: ICYMI last week: How big is Novartis's LCZ696 heart drug? Experts bet on a key number. More | Follow @JohnCFierce

@DamianFierce: $MNKD finally gets its Afrezza deal as $SNY signs up for $150M up front and $775M in milestones. Article | Follow @DamianFierce

> Otonomy and Zosano Pharma are scheduled to go public this week, seeking a combined $150 million amid an increasingly volatile market for biotech IPOs. News

> For years, drug developers have been outsourcing R&D tasks to other groups of people, but a new class of startups is working to automate much of the process and, effectively, create robotic chemists. Story

Pharma News

@FiercePharma: Top-read on FP this weekend: Pfizer faces growing legal threat over Lipitor. Article | Follow @FiercePharma

@EricPFierce: ICYMI last week: Instead of buying counterfeit Viagra from China, this guy bought APIs and whipped up an ED drug in his home lab. More | Follow @EricPFierce

@CarlyHFierce: Favorite fact I've learned so far today: The inhaler for MannKind's Afrezza inhaler is named "Dreamboat." | Follow @CarlyHFierce

> New use for Bayer's Eylea in EU gives it more market power against Novartis' Lucentis. Article

> Weber intends to build Takeda into a global player but stay true to its Japanese heritage. Story

> Former top Sanofi exec Whitaker nabbed by Synta to shuttle cancer drug to market. Report

Medical Device News

@FierceMedDev: ICYMI: Volcano guides lower but offers long-term vision, Wall Street trims by as much as 25%. Article | Follow @FierceMedDev

@StacyALawrence: Med tech M&A gets much, much bigger during the first half. Feature | Follow @StacyALawrence

@VarunSaxena2: RT @foodanddruglaw: CMS delays launch of Sunshine Act reporting website. More from The Hill | Follow @VarunSaxena2

@MichaelGFierce: Carnegie Mellon team creates self-assembling nanofibers for shaped delivery vehicles. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: Not for the faint of heart: A behind-the-scenes look at creating prosthetic eyes. More from NPR | Follow @EmilyWFierce

> Medtronic hires former senators to lobby against anti-inversion bill and protect acquisition of Covidien. Report

> Imaging pen may detect skin cancer faster. More

CRO News

> Icon charts another sales jump with eyes on a big year. Report

> Charles River's checkbook fuels a leap in revenue. More

> Quintiles and Roche take to China with testing partnership. News

> Parexel notches double-digit annual growth with a big year ahead. Article

> Deal-minded Venn buys another CRO. Story

Biotech IT News

> Actelion working with PatientsLikeMe rare cancer community on outcome measure. Report

> U.S. research institutes target standard neuroscience data format. More

> AllSeq, DNAnexus share data from Illumina HiSeq X Ten. Story

> Google rolls out preview of healthcare app development kit. Article

> The race to build a robo-chemist. Item

Animal Health News

> Cost spike of doxycycline has created sticker shock for pet owners. Report

> Zoetis CEO sees global factors coalescing to spur more growth. More

> Medical marijuana coming to the pet med market. Item

> SmartPak acquisition helps Henry Schein grow its animal health sales. Story

> Zoetis expects to have PEDv vaccine ready this year. Article

Suggested Articles

ElevateBio raised $170 million to propel six programs into the clinic and get its centralized R&D and manufacturing hub up and running.

Efforts to pivot existing discoveries into COVID-19 cures may not bear fruit until the pandemic has ended but could help fend off future outbreaks.

Regeneron's latest cholesterol fighter cut "bad" cholesterol in half for patients with a rare genetic disorder, including in hard-to-treat…